Table 2.
Summary table of the assessment of periarticular inflammation, synovitis, synovial hyperplasia, destructive damages of articular cartilage and bone tissue of the left ankle joint in the model of CFA-induced arthritis after injections of tested agents (score mean ± SEM).
| Days after CFA-induced arthritis | Study groups | Periarticular inflammation | Synovitis | Synovial hyperplasia | Articular cartilage damage | Destruction of bone tissue |
|---|---|---|---|---|---|---|
| Score | ||||||
| Day 3 | NS+NS | |||||
| CFA+NS CFA - 17.1A CFA+ Norocarp CFA+ 17.1 |
0 2.00 ± 0.20 2.00 ± 0.10 2.00 ± 0.15 2.25 ± 0.20 |
0 2.00 ± 0.19 2.00 ± 0.25 2.00 ± 0.16 2.25 ± 0.10 |
0 1.00 ± 0.11 1.00 ± 0.10 1.00 ± 0.09 1.25 ± 0.10 |
0 0 0 0 0 |
0 0 0 0 0 |
|
| Day 10 | NS+NS | |||||
| CFA+NS CFA+ 17.1A CFA+ Norocarp CFA+ 17.1 |
0 3.00 ± 0.14 2.80 ± 0.20 2.50 ± 0.16 a 2.50 ± 0.19 b |
0 3.00 ± 0.30 2.20 ± 0.17 b 2.00 ± 0.17 a 1.50 ± 0.09 b |
0 2.00 ± 0.22 1.60 ± 0.21 1.00 ± 0.13 a 1.00 ± 0.11 b |
0 1.00 ± 0.11 0.40 ± 0.12 b 1.00 ± 0.07 0 |
0 2.00 ± 0.16 1.20 ± 0.15 b 1.50 ± 0.13 1.00 ± 0.26 b |
|
| Day 21 | NS+NS | |||||
| CFA+NS CFA+ 17.1A CFA+ Norocarp CFA+ 17.1 |
0 3.00 ± 0.22 2.20 ± 0.25 b 2.33 ± 0.24 a 2.67 ± 0.30 a |
0 3.00 ± 0.27 2.00 ± 0.13 b 2.00 ± 0.21 b 2.33 ± 0.26 a |
0 1.50 ± 0.29 0.71 ± 0.09 b 1.00 ± 0.20 1.33 ± 0.18 |
0 1.00 ± 0.16 0.70 ± 0.08 b 1.00 ± 0.10 1.00 ± 0.09 |
0 2.50 ± 0.41 1.43 ± 0.12 b 1.33 ± 0.19 b 2.33 ± 0.17 |
|
Significant difference (ap < 0.05; bp < 0.01) between treated (17.1, 17.1A, Norocarp) and non-treated groups (n = 10 in each group).